ArticleHead & neck2025
Quad Shot-A Tertiary Hospital Experience With a Palliative Radiotherapy Regimen for Head and Neck Cancer.
Article in Head & neck, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- PACTUS: A two-week radiotherapy regimen for patients with anal squamous cell carcinoma unsuitable for standard chemoradiotherapy-a retrospective single-centre experience.Clinical and translational radiation oncology · 2027Article
- Review
- QUAD SHOT radiotherapy for palliation in advanced cancer: current status and future directions.Frontiers in oncology · 2026Review
- Quad Shot-A Tertiary Hospital Experience With a Palliative Radiotherapy Regimen for Head and Neck Cancer.Head & neck · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHead and neck cancer patients often present with locally advanced disease. For some patients, palliative treatment schedules focused on symptom control are often preferred. Perhaps the most widely used of these is the so-called Quad Shot (QS) regimen.
methodsWe evaluated 51 patients with head and neck squamous cell carcinomas treated with QS at University Medical Centre Mainz between 2017 and 2024 for response, survival, and toxicity.
resultsMedian overall survival was 5.9 (95% CI: 4.3-10.5) months. Thirty-nine patients could be evaluated for response; out of these, 16 patients had an objective response, and 21 patients had stable disease. Only two cases of toxicity Grade 3 or higher were observed and are most likely attributable to other reasons.
conclusionQS was well tolerated and showed a meaningful response in most patients. Using real-world data from a highly palliative patient cohort, we discuss several considerations for QS prescription.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.